AKT1 and cancer: Recovery of the PI3K/Akt pathway has previously been suggested as a driver of resistance following RTK inhibition (Goltsov et al., 2011), and this is also true for FGFR-driven cancers (Singleton et al., 2015, Wang et al., 2017, Datta et al., 2017, Packer et al., 2017).